ICU Medical Inc: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 16, 2018 and accepted by EDGAR at Mar 16, 2018, 17:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-01-01 to 2017-12-31 | $1.29bn | us-gaap:Revenues |
| Gross profit | 3 months2017-10-01 to 2017-12-31 | $137.5m | us-gaap:GrossProfit |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $426.1m | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $51.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $304.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$15.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $2.0m | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | −$17.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | $49.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | $68.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | $2.33 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | $3.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-10-01 to 2017-12-31 | $2.47 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | $3.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 20,858,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | $154.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $74.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $4.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $290.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $864.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $1.50bn | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $210.3m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2017-12-31 | $1.20bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000883984-18-000010. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.